MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- PFIZER LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Pfizer Quarterly Results (PFIZ)
Here are the latest quarterly results of Pfizer. For more details, see the Pfizer financial fact sheet and Pfizer share price and chart. For a sector overview, read our pharmaceuticals sector report.
Pfizer Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 4,565 | 5,200 | 5,123 | 5,197 | 5,138 | 5,357 | 5,444 | 5,671 | |
| Other income | Rs m | 321 | 312 | 305 | 371 | 644 | 355 | 358 | 448 | |
| Turnover | Rs m | 4,886 | 5,512 | 5,428 | 5,568 | 5,781 | 5,711 | 5,802 | 6,118 | |
| Expenses | Rs m | 3,386 | 3,813 | 3,822 | 3,900 | 3,595 | 3,847 | 3,782 | 4,029 | |
| Gross profit | Rs m | 1,179 | 1,385 | 1,301 | 1,298 | 1,543 | 1,510 | 1,662 | 1,642 | |
| Depreciation | Rs m | 177 | 173 | 183 | 177 | 178 | 176 | 250 | 251 | |
| Interest | Rs m | 2 | -1 | 2 | 2 | 3 | 6 | 22 | 26 | |
| Profit before tax | Rs m | 1,321 | 1,525 | 1,422 | 1,489 | 2,006 | 1,682 | 1,749 | 1,812 | |
| Tax | Rs m | 448 | 480 | 504 | 531 | 687 | 588 | 621 | 269 | |
| Profit after tax | Rs m | 872 | 1,045 | 918 | 958 | 1,319 | 1,095 | 1,128 | 1,543 | |
| Gross profit margin | % | 25.8 | 26.6 | 25.4 | 25.0 | 30.0 | 28.2 | 30.5 | 29.0 | |
| Effective tax rate | % | 33.9 | 31.5 | 35.4 | 35.7 | 34.2 | 34.9 | 35.5 | 14.9 | |
| Net profit margin | % | 19.1 | 20.1 | 17.9 | 18.4 | 25.7 | 20.4 | 20.7 | 27.2 | |
| Diluted EPS | Rs | 19.1 | 22.8 | 20.1 | 20.9 | 28.8 | 23.9 | 24.7 | 33.7 | |
| Diluted EPS (TTM) | Rs | 70.7 | 78.7 | 86.3 | 82.9 | 92.7 | 93.8 | 98.4 | 111.1 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Pfizer 2QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: LUPIN INDOCO REMEDIES DISHMAN PHARMA PIRAMAL ENTERPRISES GSK PHARMA
Compare PFIZER With: LUPIN INDOCO REMEDIES DISHMAN PHARMA PIRAMAL ENTERPRISES GSK PHARMA
Compare PFIZER With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Scales 42,000 and Smallcaps Rebound: What Happens Next?(Podcast)
This week, the BSE Sensex crossed 42,000 level for the first time. While Nifty followed suit, hitting a record high of 12,377.
Views on news
PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)
Oct 29, 2019 | Updated on Oct 29, 2019For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.
PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.
PFIZER 2017-18 Annual Report Analysis (Annual Result Update)
Jan 1, 2019 | Updated on Jan 1, 2019Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
My Latest Stock Recommendation (Fast Profits Daily)
Jan 10, 2020The story behind my latest stock recommendation and an important announcement.
Saffron Curtain = Hindutva Rate of Growth? (The Honest Truth)
Jan 8, 2020Will the Indian economy revert to a sub-3% growth rate?
Multibaggers of the Next Decade (The 5 Minute Wrapup)
Jan 6, 2020The one key ingredient to be seen amongst top multibaggers of the next decade
Your Safe Income Options for 2020 (Fast Profits Daily)
Jan 9, 2020What are you safest investing options in 2020 when interest rates fall.
I Made a Killing in the Markets this Week... Here's How (Profit Hunter)
Jan 10, 2020How we made a killing in the markets amidst geopolitical tension and war mongering.
More|
| |
OUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- A Simple Test to Find out If a Stock Has 100x Potential
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
PFIZER SHARE PRICE
Jan 17, 2020 (Close)
TRACK PFIZER
- Track your investment in PFIZER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PFIZER
PFIZER - NOVARTIS COMPARISON
COMPARE PFIZER WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.